Long-Term Efficacy of Baricitinib in the Treatment of Alopecia Areata: Results at Week 104 from the BRAVE-AA1 and BRAVE-AA2 Studies

This analysis evaluates the long-term efficacy of continuous baricitinib treatment over two years in adults with severe alopecia (hair loss ≥ 50%) from two phase 3 trials (BRAVE-AA1 and BRAVE-AA2). Patients were randomized to receive either 2 mg or 4 mg of baricitinib and treated up to week 104 (S 104). Among those who responded to treatment by week 52 (S 52), 90.7% (117/129) on 4 mg and 89.2% (58/65) on 2 mg maintained a SALT score ≤ 20 at S 104. Additionally, significant proportions of patients showed complete or near-complete regrowth of eyebrows and eyelashes. For those with a SALT score > 20 at S 52, 39.1% (43/110) achieved a SALT score ≤ 20 by S 104. The study concludes that baricitinib's efficacy in treating severe alopecia is sustained up to 104 weeks, with some patients requiring long-term treatment for optimal results.